SUBSCRIBE
SUBSCRIBE

Ultragenyx Pharmaceutical Inc.

NEWS
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Biotech Bay
Nine Bay Area Biotechs Vie to be the “Next Genentech”
May 24, 2016
 · 
4 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Arcturus Therapeutics Stands to Collect Up to $1.66 Billion from Rare Disease Pact with Ultragenyx
October 29, 2015
 · 
3 min read
Load More
AWARDS
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
June 4, 2026
 · 
1 min read
Press Releases
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 22, 2026
May 24, 2026
 · 
1 min read
Press Releases
Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference
May 7, 2026
 · 
1 min read
Press Releases
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update
May 6, 2026
 · 
13 min read
Press Releases
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update
April 29, 2026
 · 
1 min read
Press Releases
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 24, 2026
April 26, 2026
 · 
1 min read
Press Releases
Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
April 2, 2026
 · 
7 min read
Press Releases
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy
March 30, 2026
 · 
7 min read
Press Releases
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - March 20, 2026
March 23, 2026
 · 
1 min read
Press Releases
Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
March 13, 2026
 · 
9 min read
Load More